Plandai Biotechnology (Plandai Biotechnology) Change In Working Capital : $0.04 Mil (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Plandai Biotechnology Change In Working Capital?

Plandai Biotechnology's change in working capital for the quarter that ended in Jun. 2023 was $0.04 Mil.

Plandai Biotechnology's change in working capital for the fiscal year that ended in Jun. 2023 was $0.04 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Plandai Biotechnology Change In Working Capital Historical Data

The historical data trend for Plandai Biotechnology's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plandai Biotechnology Change In Working Capital Chart

Plandai Biotechnology Annual Data

Trend

Mar09

Mar10

Mar11

Jun12

Jun13

Jun14

Jun15

Jun16

Jun22

Jun23

Change In Working Capital

Get a 7-Day Free Trial

-0.01

0.98

1.35

0.10

0.04

Plandai Biotechnology Semi-Annual Data
	Mar03	Mar04	Mar05	Mar06	Mar07	Mar08	Mar09	Mar10	Mar11	Jun12	Jun13	Jun14	Jun15	Jun16	Jun22	Jun23
Change In Working Capital	Get a 7-Day Free Trial											-0.01	0.98	1.35	0.10	0.04

Plandai Biotechnology Change In Working Capital Calculation

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2023 was $0.04 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Plandai Biotechnology Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Plandai Biotechnology's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Plandai Biotechnology (Plandai Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Plandai Biotechnology Inc (OTCPK:PLPL) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

4811 49th Street, San Diego, CA, USA, 92115

Website

http://www.plandaibiotech.com

Plandai Biotechnology Inc. manufactures highly bioavailable extracts from live plant materials.

Executives

Callum Baylis-duffield	director	FLAT 37 ISLAND HOUSE THREE MILL LANE, LONDON ENGLAND X0 E33AF
Timothy Matula	other: Former Director	175 JACKSON AVE N, SUITE 102, MINNEAPOLIS MN 55343
Brian Johnson	director	P.O. BOX 1594, FERNDALE WA 98248-1594
Roger Duffield	director, officer: President, Secretary and CFO	2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
Daron Baylis Duffield	director	2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
David Rzepnicki	director	21 HORIZON DRIVE, SARATOGA SPRINGS NY 12866